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Abstract
Background: Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose
of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-
specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-
SM.
Methods: Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were
extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function
(CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model
was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year
cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves
were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve
analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile
values of the nomogram-based scores, and their survival differences were assessed using CIF curves.
Results: The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM,
respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were
related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and
5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were
almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more
benefit when the threshold probabilities were set within the ranges of 0.24–0.89 and 0.25–0.91 for 3-year and 5-
year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of
LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001).
Conclusions: The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM.
With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment
protocols and follow-up schedules.
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Background
Adenosquamous carcinoma (ASC), a rare histological
subtype of lung cancer, accounts for less than 3% of
all lung cancer cases [1–4]. In general, ASC is defined
as a carcinoma with an adenocarcinoma (ADC) com-
ponent and a squamous cell carcinoma (SCC) compo-
nent each exceeding 10% of the entire tumour [5].
There is a substantial difference between ASC and
other histological subtypes of lung cancer regarding
clinicopathological characteristics. ASC patients are
more likely to present with a larger tumour size, a
higher frequency of lymphatic/pleural invasion, and a
worse histological grade than ADC and SCC patients
[3, 6]. In terms of survival, ASC patients have an un-
favourable prognosis compared to ADC and SCC pa-
tients [3, 6, 7].
The majority of ASC patients are diagnosed at an age
over 60 years [3, 6, 7], and elderly patients tend to have a
higher prevalence of comorbidities than younger patients
[8]. In addition, the presence of comorbidities has been
suggested to be a strong predictor of other cause-
specific mortality (OCSM) in various cancers [9–11].
Considering the high risk of OCSM, it is essential to
take OCSM into account when performing survival
analysis for lung ASC. However, in the presence of com-
peting events (such as OCSM), a traditional Cox propor-
tional hazards model is no longer suitable, as it ignores
the existence of competing risks, which may inevitably
overestimate the incidence of cancer-specific mortality
[12]. In this context, the competing risk model is super-
ior to the conventional Cox model because it takes into
consideration competing events and can differentiate be-
tween the effects of therapy and risk factors on specific
events [12, 13]. However, to date, there are no studies
that have adopted a competing risk model to examine
the factors influencing the prognosis of patients with
lung ASC.
In addition, nomograms, which provide a visual dis-
play of a linear prediction model, can be used to cal-
culate the individual risk probabilities of a clinical
event based on the predictive variables in the graph
[14]. Because of their usefulness, nomograms have
been extensively applied in various cancers, such as
non-small-cell lung cancer (NSCLC) [15], hepatocellu-
lar carcinoma [16], and breast cancer [17]. However,
to our knowledge, there are no studies using a com-
peting risk regression model to develop a nomogram
to predict the survival of lung ASC patients.
Therefore, a competing risk analysis was performed to
determine the predictive factors for lung cancer-specific
mortality (LC-SM) in patients with lung ASC. We devel-
oped a nomogram to offer clinicians a quantitative
means to assess the individual cumulative incidences of
LC-SM to improve clinical decision making.
Methods
Data sources
Data on patients with first primary lung ASC histologi-
cally diagnosed between 2004 and 2015 were extracted
from the Surveillance, Epidemiology, and End Results
(SEER) registries (1975–2016 dataset). The study popu-
lation comprised patients with the International Classifi-
cation of Diseases for Oncology, Third Edition (ICD-O-
3) site code C340-C349 and histological code 8560/3.
The study time span was set from 2004 to 2015 on the
basis of the first year of the American Joint Committee
Fig. 1 Flow diagram presenting the screening process in the
SEER database
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Table 1 Cumulative incidences of death among patients with ASC
Variables Nt (%) Ne (%) LC-SM (%) OCSM (%)
3-year (95% CI) 5-year (95% CI) P 3-year (95% CI) 5-year(95% CI) P
Total 2705 1897 49.6 (47.7–51.5) 55.8 (53.8–57.8) 8.2 (7.1–9.2) 11.8 (10.5–13.1)
Age (years)
median (IQR) 69 (61–76) 70 (62–77)
< 65 years 929 (34.3) 608 (32.1) 49.2 (45.9–52.4) 55.0 (51.6–58.3) 0.275 5.1 (3.7–6.5) 8.0 (6.2–9.9) < 0.001
≥ 65 years 1776 (65.7) 1289 (67.9) 49.9 (47.5–52.2) 56.3 (53.8–58.7) 9.8 (8.4–11.2) 13.9 (12.2–15.6)
Sex 0.002 0.421
Female 1268 (46.9) 858 (45.2) 45.8 (43.0–48.6) 52.4 (49.5–55.3) 8.3 (6.8–9.9) 11.9 (10.0–13.8)
Male 1437 (53.1) 1039 (54.8) 53.0 (50.4–55.6) 58.8 (56.1–61.5) 8.0 (6.6–9.5) 11.8 (10.0–13.6)
Race 0.008 0.027
Black 262 (9.7) 195 (10.3) 56.8 (50.7–63.0) 62.9 (56.7–69.1) 7.0 (3.9–10.2) 12.4 (8.0–16.8)
White 2248 (83.1) 1571 (82.8) 48.4 (46.3–50.5) 54.4 (52.2–56.6) 8.6 (7.4–9.8) 12.2 (10.8–13.7)
Other race 195 (7.2) 131 (6.9) 54.3 (46.9–61.7) 63.1 (55.6–70.6) 4.3 (1.4–7.3) 6.0 (2.3–9.7)
Marital status 0.018 0.455
Married 1590 (58.8) 1091 (57.5) 48.1 (45.5–50.6) 54.2 (51.6–56.8) 7.9 (6.5–9.2) 11.3 (9.7–13.0)
Unmarried 1115 (41.2) 806 (42.5) 51.9 (48.9–54.9) 58.1 (55.1–61.2) 8.6 (6.9–10.3) 12.6 (10.5–14.7)
Tumour site < 0.001 0.213
Upper lobe 1651 (61.0) 1130 (59.6) 47.8 (45.3–50.3) 53.7 (51.2–56.3) 8 (6.7–9.4) 12 (10.3–13.7)
Middle lobe 113 (4.2) 79 (4.2) 42.4 (33.1–51.7) 53.8 (43.7–63.8) 11.2 (5.1–17.2) 18.6 (10.6–26.6)
Lower lobe 838 (31.0) 605 (31.9) 52.3 (48.8–55.7) 58.2 (54.7–61.7) 8.5 (6.5–10.4) 11.4 (9.1–13.7)
Main bronchus 58 (2.1) 53 (2.8) 82 (71.6–92.5) 86.8 (76.9–96.7) 5.2 (0–11) 5.2 (0–11.0)
Overlapping lesion 45 (1.7) 30 (1.6) 42.8 (28–57.6) 52.8 (37.5–68.0) 4.6 (0–11) 7.1 (0–15.0)
Tumour laterality 0.131 0.165
Right 1564 (57.8) 1105 (58.2) 48.7 (46.2–51.2) 55.2 (52.6–57.8) 8.6 (7.2–10) 12.9 (11.1–14.7)
Left 1135 (42.0) 787 (41.5) 50.8 (47.9–53.8) 56.4 (53.4–59.4) 7.6 (6–9.2) 10.4 (8.5–12.3)
Bilateral 6 (0.2) 5 (0.3) 66.7 (22.2–111.2) 83.3 (43.8–100) 0 (0–0) 0 (0–0)
Grade < 0.001 < 0.001
Grade I 35 (1.3) 21 (1.1) 21.1 (6.8–35.3) 21.1 (6.8–35.3) 21.5 (7–36) 25.6 (9.6–41.5)
Grade II 857 (31.7) 529 (27.9) 38.2 (34.8–41.5) 45.9 (42.4–49.5) 7.5 (5.7–9.3) 12.8 (10.4–15.3)
Grade III 1751 (64.7) 1294 (68.2) 55.4 (53.1–57.8) 61.1 (58.7–63.5) 8.3 (6.9–9.6) 11.1 (9.5–12.6)
Grade IV 62 (2.3) 53 (2.8) 60.1 (47.7–72.6) 62.1 (49.6–74.6) 8.2 (1.2–15.2) 12.2 (3.5–20.8)
T stage < 0.001 < 0.001
T1 736 (27.2) 402 (21.2) 26.8 (23.5–30.1) 32.8 (29.2–36.4) 9.4 (7.2–11.6) 16.3 (13.3–19.2)
T2 1213 (44.8) 839 (44.2) 47.2 (44.4–50.1) 54.2 (51.3–57.2) 9 (7.4–10.7) 12.1 (10.2–14.0)
T3 211 (7.8) 174 (9.2) 68.9 (62.5–75.3) 74.6 (68.4–80.9) 6.6 (3.1–10.1) 9.9 (5.5–14.4)
T4 545 (20.1) 482 (25.4) 78.2 (74.6–81.7) 83.1 (79.7–86.5) 5.2 (3.3–7.1) 6.1 (4.0–8.2)
N stage < 0.001 < 0.001
N0 1475 (54.5) 892 (47.0) 33.8 (31.4–36.3) 40.6 (38.0–43.2) 9.6 (8–11.1) 14.9 (12.9–16.9)
N1 362 (13.4) 245 (12.9) 51.5 (46.2–56.7) 58.6 (53.2–64.0) 5.6 (3.1–8) 8.3 (5.2–11.4)
N2 711 (26.3) 617 (32.5) 73.8 (70.5–77.1) 79.2 (76.0–82.3) 7 (5.1–8.9) 8.3 (6.2–10.4)
N3 157 (5.8) 143 (7.5) 85.1 (79.2–91.0) 87.3 (81.5–93.2) 6.6 (2.6–10.5) 6.6 (2.6–10.5)
M stage < 0.001 < 0.001
M0 2108 (77.9) 1344 (70.8) 39.8 (37.7–42) 46.9 (44.7–49.2) 8.9 (7.6–10.1) 13.3 (11.8–14.9)
M1 597 (22.1) 553 (29.2) 84.2 (81.2–87.1) 87.1 (84.2–89.9) 5.8 (3.9–7.7) 6.5 (4.5–8.6)
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on Cancer (AJCC) 6th edition (2004+) and a minimum
of one-year follow-up.
Related demographic and clinicopathological variables
were collected, including age, sex, race, marital status,
tumour laterality, tumour site, histological grade, TNM
stage, surgical treatment, survival time, and causes of
death. We excluded patients with any unknown variable
values mentioned above. Age was categorized as < 65 years
and ≥ 65 years; marital status was divided into unmarried
and married; histological grade was classified into grade I
(well differentiated), grade II (moderately differentiated),
grade III (poorly differentiated), and grade IV (undifferen-
tiated); and causes of death were categorized as alive, LC-
SM and OCSM. As no radiation and unknown radiation
have been merged into “None/Unknown” since 2016, and
there was a substantial heterogeneity in chemotherapy, we
did not include radiation and chemotherapy as variables
in the present study. The detailed screening process is dis-
played in Fig. 1.
Statistical analysis
Continuous variables with a normal distribution are
expressed as the mean ± standard deviation (SD), and
continuous variables with a skewed distribution are pre-
sented as the median (interquartile range, IQR). In the
competing risk model, OCSM was regarded as a com-
peting event for LC-SM. First, we computed the cumula-
tive incidence function (CIF) for LC-SM and OCSM.
Further subgroup analysis was carried out according to
age, sex, race, marital status, tumour laterality, tumour
site, histological grade, TNM stage, and surgery, and
corresponding CIF curves were plotted for these vari-
ables. The significant differences in CIF values among
subgroups were evaluated by Gray’s test [18]. Second,
for the purpose of developing a competing risk regres-
sion model for LC-SM, the data set was randomly split
into a training cohort (2/3) and a validation cohort (1/3).
In total, 1803 cases serving as the training cohort were
employed for model development, and 902 cases serving
as the validation cohort were used for model validation.
Third, variables that were perceived as clinically relevant
beforehand or considered significant in the univariate
analysis (P < 0.1) were introduced into a stepwise com-
peting risk regression model. Subsequently, the optimal
regression model was fitted when incorporating the pre-
dictive variables selected by the stepwise regression pro-
cedure. Fourth, we calculated the subdistribution hazard
ratio (SHR) of the included variables for LC-SM based
on the multivariate competing risk model, and a nomo-
gram on the basis of the coefficients from the model was
developed. To evaluate the model performance, the con-
cordance index (C-index) was utilized to estimate the
predictive accuracy (discrimination), and calibration
curves (agreement between the observed probability and
predicted probability at a certain time point) were con-
structed to assess the calibration with the aid of the R
package “riskRegression” [19]. We also performed ten-
fold cross validation for all data sets which were ran-
domly partitioned into ten equal-sized subsamples [20].
Finally, decision curve analysis (DCA) was conducted to
assess the clinical usefulness and net benefit of the com-
peting risk model [21]. To determine whether the nomo-
gram could successfully distinguish high-risk from low-
risk lung ASC patients, each patient’s prediction score
was derived according to the nomogram, and the
patients were categorized into the high-risk, medium-
risk, and low-risk groups based on the tertile values
of the risk scores. Subsequently, the corresponding
CIF curves of the three groups were plotted for the
training set and validation set, and the significant dif-
ferences in CIF were assessed using Gray’s test. All
statistical analyses were carried out employing the R
software version 3.5.2. A two-tailed P < 0.05 was con-
sidered statistically significant.
Results
The baseline characteristics of the whole study cohort
are presented in Table 1. In general, a total of 2705 lung
Table 1 Cumulative incidences of death among patients with ASC (Continued)
Variables Nt (%) Ne (%) LC-SM (%) OCSM (%)
3-year (95% CI) 5-year (95% CI) P 3-year (95% CI) 5-year(95% CI) P
AJCC Stage < 0.001 < 0.001
I 1142 (42.2) 624 (32.9) 23.9 (21.4–26.4) 31.1 (28.3–34.0) 11.2 (9.3–13.1) 17.2 (14.8–19.6)
II 332 (12.3) 213 (11.2) 47.1 (41.6–52.6) 52.7 (47.1–58.4) 5.7 (3.1–8.3) 9.4 (6.0–12.8)
III 634 (23.4) 507 (26.7) 64.9 (61.1–68.8) 72.8 (69.1–76.5) 6.3 (4.3–8.2) 8.4 (6.0–10.7)
IV 597 (22.1) 553 (29.2) 84.2 (81.2–87.1) 87.1 (84.2–89.9) 5.8 (3.9–7.7) 6.5 (4.5–8.6)
Surgery < 0.001 < 0.001
No 886 (32.8) 806 (42.5) 82.1 (79.5–84.7) 85.9 (83.4–88.5) 7.9 (6.1–9.7) 8.8 (6.8–10.8)
Yes 1819 (67.2) 1091 (57.5) 34.1 (31.8–36.3) 41.7 (39.3–44.0) 8.3 (7–9.6) 13.3 (11.6–15.0)
Abbreviations: Nt total number, Ne number of death events, ASC adenosquamous carcinoma, CI confidence interval, LC-SM lung cancer-specific mortality, OCSM
other cause-specific morality, AJCC American Joint Committee on Cancer, IQR interquartile range
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Fig. 2 Cumulative incidence function curves of death for patients with lung ASC by different characteristics (solid line: LC-SM; dotted line: OCSM).
Abbreviations: ASC: adenosquamous carcinoma; LC-SM: lung cancer-specific mortality; OCSM: other cause-specific morality
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ASC patients were identified in the SEER database. For
these patients, the median age at diagnosis was 69 years
(IQR: 61–76). A larger proportion of patients were aged
above 65 years (1776, 65.7%), male (1437, 53.1%), mar-
ried (1590, 58.8%), and white (2248, 83.1%). The major-
ity of tumours were located in the upper lobe (1651,
61.0%) and on the right side (1564, 57.8%). Most patients
were diagnosed with histological grade III (64.7%),
followed by grade II (31.7%), grade IV (2.3%), and grade
I (1.3%). The distribution of AJCC stage was as follows:
42.2% had stage I, 12.3% had stage II, 23.4% had stage
III, and 22.1% had stage IV. A total of 67.2% of patients
received surgical treatment.
The median follow-up of the whole study cohort was
21months (IQR: 8–52). In total, 1895 (70.1%) patients
died throughout the whole follow-up period, of whom
1535 (81.0%) died due to lung cancer and 362 (19.0%)
died due to non-lung cancer causes. The 3-year and 5-
year cumulative incidences of LC-SM and OCSM by dif-
ferent clinicopathological characteristics are displayed in
Table 1, and the corresponding CIF curves are presented
in Fig. 2. Overall, the 3-year and 5-year LC-SM rates
were 49.6% (CI: 47.7–51.5%) and 55.8% (CI: 53.8–
57.8%), respectively, while the 3-year and 5-year OCSM
rates were 8.2% (CI: 7.1–9.2%) and 11.8% (CI: 10.5–
13.1%).
Fig. 3 Forest plots visualizing the SHRs of the clinicopathological characteristics for LC-SM using the univariate competing risk model.
Abbreviations: LC-SM: lung cancer-specific mortality; SHR: subdistribution hazard ratio
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Subsequently, both univariate and multivariate com-
peting risk models were adopted to evaluate the LC-SM
of lung ASC patients. In univariate analysis, male sex,
unmarried status, black race, main bronchus, advanced
TNM stage, advanced histological grade, and surgical
treatment were related to significantly higher incidences
of LC-SM, whereas there were no significant differences
for age and tumour laterality (Fig. 3). In multivariate
analysis, age, sex, surgery, T stage, N stage, and M stage
were independent predictive factors for LC-SM (Table 2).
In detail, increasing age was associated with an increased
probability of LCSM. Male sex was related to a signifi-
cantly higher likelihood of LCSM (1.26, CI: 1.10–1.43),
while surgery was related to a significantly lower likeli-
hood of LC-SM (0.45, CI: 0.37–0.53). Compared with
patients with T1, advanced T-stage patients were more
likely to face LCSM, with SHRs of 1.44 (1.21–1.72), 2.24
(1.72–2.92), and 1.99 (1.59–2.49) for T2, T3, and T4 pa-
tients, respectively. A similar phenomenon was observed
among advanced N-stage patients compared with N0 pa-
tients, with SHRs of 1.52 (1.26–1.84), 1.57 (1.32–1.87),
and 1.51 (1.12–2.03) for N1, N2, and N3 patients,
respectively.
A nomogram on the basis of the competing risk
models was developed to calculate the 3-year and 5-year
cumulative LC-SM probabilities (Fig. 4). For each pa-
tient, first locate the values of different variables on the
corresponding rows and then draw vertical lines point-
ing to the “Points” row to obtain corresponding scores.
For instance, for a male patient, by drawing a vertical
line straight up to the “Point” row, we would obtain
Table 2 Multivariate competing risk model for LC-SM in
patients with lung ASC





Male 0.228 1.26 (1.13–1.40) < 0.001
Surgery
No
Yes −0.798 0.45 (0.39–0.52) < 0.001
T stage
T1 Reference Reference
T2 0.416 1.52 (1.30–1.77) < 0.001
T3 0.817 2.26 (1.82–2.81) < 0.001
T4 0.783 2.19 (1.82–2.63) < 0.001
N stage
N0 Reference Reference
N1 0.398 1.49 (1.26–1.76) < 0.001
N2 0.5 1.65 (1.43–1.90) < 0.001
N3 0.469 1.60 (1.28–2.00) < 0.001
M stage
M0 Reference Reference
M1 0.477 1.61 (1.40–1.86) < 0.001
Abbreviations: ASC adenosquamous carcinoma, CI confidence interval, LC-SM
lung cancer-specific mortality, SHR subdistribution hazard ratio
Fig. 4 Competing risk nomogram predicting the 3-year and 5-year cumulative probabilities of death for LC-SM in patients with lung ASC.
Abbreviations: ASC: adenosquamous carcinoma; LC-SM: lung cancer-specific mortality
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approximately 28 points. Similarly, this process is per-
formed for the other variables. By adding up these
scores, a total score can be obtained and is located on
the “Total Points” row. Subsequently, a vertical line can
be drawn straight down to acquire the 3-year or 5-year
cumulative death probabilities. For example, if the total
score was 100, the corresponding 3-year and 5-year
probabilities of LC-SM would be approximately 30 and
36%, respectively.
The calibration curves accompanied by C-indexes are
displayed in Fig. 5. As shown in Fig. 5, the calibration
curves are close to the 45-degree diagonal line, indicat-
ing that the developed nomogram is well calibrated
(good agreement between the observed mortality prob-
ability and the predicted mortality probability). Add-
itionally, the 3-year and 5-year C-indexes for the
nomogram predicting the probabilities of LC-SM were
0.83 (CI, 0.78–0.87) and 0.82 (CI, 0.73–0.90) for the
training cohort, and 0.79 (CI, 0.75–0.84) and 0.79 (CI,
0.71–0.88) for the validation cohort, respectively, which
indicated superb model discrimination. The ten-fold
cross validation C-indexes are shown in Table 3. The
adjusted 3-year and 5-year C-indexes were 0.81 (CI,
0.80–0.83) and 0.81 (CI, 0.80–0.83), respectively. Overall,
the 3-year or 5-year C-indexes of the cross validation
were almost equal to those of the training set or valid-
ation set, which indicated robust model performance.
The outcomes of DCA are shown in Fig. 6a, which
shows that the clinical net benefit gained from the com-
peting risk model was higher than that in the hypothet-
ical non-screening or all-screening scenarios, when the
threshold probabilities were within the range of 0.24–
0.89 and 0.25–0.91 for 3-year and 5-year LCSM, respect-
ively. According to the tertile values (117.1 and 180.5) of
the nomogram-based scores derived from the training
cohort, the patients were categorized into high-risk,
medium-risk, and low-risk groups in the training cohort
and validation cohort. As displayed in Fig. 6b-c, the
high-risk group had the highest probabilities of LC-SM,
followed by the medium-risk group and the low-risk
group in the training cohort and validation cohort (both
P < 0.0001). Therefore, when using the nomogram as a
predictive tool, clinicians could successfully discriminate
among different risk groups.
Fig. 5 The 3-year and 5-year calibration curves accompanied by C-indexes for the training cohort and validation cohort. The X-axes represent the
mean predicted mortality probability according to the prediction model. The Y-axes represent the observed cumulative incidence of mortality.
The grey diagonal line indicates equality between the predicted and observed values. Abbreviations: LC-SM: lung cancer-specific mortality
Table 3 C-indexes of the predictive model for patients with ASC
Cohort C-indexes Adjusted C-indexes
3-year 5-year 3-year 5-year
Training cohort
LC-SM 0.83 (CI, 0.78–0.87) 0.82 (CI, 0.73–0.90)
Validation cohort
LC-SM 0.79 (CI, 0.75–0.84) 0.79 (CI, 0.71–0.88)
Overall cohort
LC-SM 0.81 (CI, 0.80–0.83) 0.81 (CI, 0.80–0.83)
Note: Adjusted C-indexes of the model were calculated using ten-fold cross validation
Abbreviations: ASC adenosquamous carcinoma, CI confidence interval, LC-SM lung cancer-specific mortality
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Discussion
In the present study, a competing risk analysis was per-
formed to investigate the predictive factors for LC-SM
in patients with primary lung ASC from the SEER data-
base. Of the 2705 total patients, 1535 (81.0%) died from
lung cancer and 362 (19.0%) died from non-lung cancer
causes. The 5-year CIFs for LC-SM and OCSM were
55.8 and 11.8%, respectively. We constructed a nomo-
gram, which functions as a simple and useful clinical
tool, to predict the individual probabilities of LC-SM for
lung ASC patients, and the nomogram was demon-
strated to have excellent clinical usefulness.
With regard to LC-SM, T stage, N stage, and M stage
were significant independent predictive factors, unani-
mous with the eighth edition of the AJCC NSCLC sta-
ging system [22]. In addition, we also identified other
important predictors, such as age, sex, and surgery,
which have been incorporated into our nomogram.
These predictors of an increased LC-SM, including
advanced age, male sex, and surgery, have been proven
in other studies [23, 24]. For example, a recent retro-
spective study investigating NSCLC based on the SEER
database found that advanced age and male sex were re-
lated to decreased lung cancer-specific survival, and any
form of surgical resection conferred a decreased risk of
LC-SM [23]. H Zhou et al. analysed data from patients
with radically resected stage I NSCLC in the SEER data-
base and discovered that advanced age and male sex
were correlated with a higher risk of cause-specific death
[24]. As the AJCC staging system does not include im-
portant risk factors (including age, sex and surgery), the
nomogram we developed was more discriminative and
Fig. 6 DCA based on the predictive model for the 3-year and 5-year LC-SM, and CIF curves of LC-SM among different risk groups. a The x-axis
represents the threshold probability, and the y-axis represents the net benefit. The black and red dotted oblique lines reflect the assumption that
all patients die due to LC-SM, and the black horizontal dotted line reflects the assumption that no patients die due to LC-SM. The black and red
solid lines represent the threshold probability range, within which utilizing the nomogram to predict the LCSM gains more benefit than the
hypothetical treat-all or treat-none scenarios. b-c CIF curves with the P-value of Gray’s test for the training cohort and validation cohort. Abbreviations:
LC-SM: lung cancer-specific mortality; CIF: cumulative incidence function; DCA: decision curve analysis
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capable of providing a more accurate prognostic predic-
tion for individual patients.
For the sake of patient counselling and clinical deci-
sion making, it is imperative to evaluate prognosis ac-
cording to individual risk profiles. With the aid of a
prognostic nomogram, clinicians can more expediently
devise treatment protocols and follow-up strategies. Not-
ably, competing risk nomograms have been developed
for various cancers, such as nasopharyngeal carcinoma,
breast cancer, gastrointestinal stromal tumours and mel-
anoma [25–28]. However, as far as we know, this is the
first study that constructed a competing risk nomogram
based on a proportional subdistribution hazard model to
predict the individual probabilities of LC-SM for lung
ASC patients.
To assess the clinical usefulness of the nomogram, DCA
was employed to determine whether the nomogram-based
decisions could improve patients’ survival outcomes. Our
findings showed that using the nomogram to predict LC-
SM added more benefits than either the hypothetical
treat-all-patients or treat-none scenarios as long as the
threshold probabilities were within the range of 0.24–0.89
and 0.25–0.91 for 3-year and 5-year LCSM, respectively.
In addition, with the assistance of the nomogram, clini-
cians could successfully discriminate among different risk
groups, thereby making wiser clinical decisions. Therefore,
the developed nomogram can be extremely useful in the
processes of clinical practice.
The major strengths of the present study are that it
had a large enough sample size and adopted a competing
risk model to perform survival analysis. In general, the
SEER database, covering approximately 27.8% of the US
population, offers a sufficiently large sample to investi-
gate predictive factors and further develop a model-
based prognostic nomogram. Moreover, findings derived
from the analysis based on the population-based data-
base are more generalizable and representative than
those from single-centre studies [29]. Moreover, the
competing risk model fully takes into consideration any
competing events, which renders the results more un-
biased. Notably, the variables presented in the nomo-
gram can be easily collected from routine medical
records, so clinicians can more expediently predict cu-
mulative death probabilities for lung ASC patients.
Undoubtedly, there are several limitations in this
study. First, some known prognostic variables, such as
cigarette smoking, chemotherapy, radiation therapy, and
comorbidities, were not incorporated into the model.
Thus, the nomogram only functions as a reference tool
for clinicians to make clinical decisions. Further study is
warranted to incorporate these variables into future re-
search. Second, as the whole study population was from
the US, the findings of the present study may not be
generalizable to populations of other countries. Finally,
although our model exhibits excellent performance in
predicting the probabilities of LC-SM (with C-indexes
fluctuating around 0.8), an external validation cohort in-
cluding other patients is still necessary to demonstrate
the model accuracy further.
Conclusions
In conclusion, this is the first study using a competing
risk model to evaluate the cumulative incidence of LC-
SM for patients with lung ASC. We further developed a
competing risk nomogram, and the nomogram displayed
an excellent discrimination and calibration. With the aid
of this individualized predictive tool, clinicians can more
expediently devise appropriate treatment protocols and
follow-up schedules.
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